Skip to content

KLRS KLRS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co. logo
Merck & Co.MRK
$157M+726%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$163.1M+169%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$166.79M+10.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$294K-93.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$922K+644%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$3.11M+120%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's stock issuance proceeds?
KLRS (KLRS) reported stock issuance proceeds of $74K in Q1 2026.
How has KLRS's stock issuance proceeds changed year-over-year?
KLRS's stock issuance proceeds decreased by 99.3% year-over-year, from $10.5M to $74K.
What is the long-term trend for KLRS's stock issuance proceeds?
Over 2 years (2021 to 2025), KLRS's stock issuance proceeds has grown at a 1245.5% compound annual growth rate (CAGR), from $232K to $42M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.